Next Article in Journal
Occupational Exposure to Electromagnetic Fields and Health Surveillance according to the European Directive 2013/35/EU
Next Article in Special Issue
The Impact of Neglected Tropical Diseases (NTDs) on Women’s Health and Wellbeing in Sub-Saharan Africa (SSA): A Case Study of Kenya
Previous Article in Journal
The Mediating Effect of Depression on the Relationship between Social Support, Spirituality and Burnout in Family Members of Patients with Cancer
Previous Article in Special Issue
Add-On Effect of Postural Instructions to Abdominopelvic Exercise on Urinary Symptoms and Quality of Life in Climacteric Women with Stress Urinary Incontinence. A Pilot Randomized Controlled Trial
Article

Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study

1
Department of Movement, Human and Health Sciences, Health Sciences Section, University Foro Italico of Rome, 00135 Rome, Italy
2
Department of Theoretical and Applied Sciences, eCampus University, 22060 Novedrate, Italy
3
IMM-CNR, Institute for Microelectronics and Microsystems, 40129 Bologna, Italy
4
Department of Experimental Medicine, Medical Pathophysiology, Endocrinology and Nutrition Section, University Sapienza of Rome, 00185 Rome, Italy
5
Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy
6
Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, 00185 Rome, Italy
*
Authors to whom correspondence should be addressed.
Equal contribution (C.M. and G.Z.).
Academic Editor: Colin W. Binns
Int. J. Environ. Res. Public Health 2021, 18(4), 1728; https://doi.org/10.3390/ijerph18041728
Received: 20 December 2020 / Revised: 3 February 2021 / Accepted: 4 February 2021 / Published: 10 February 2021
(This article belongs to the Special Issue Feature Papers in Women's Health)
Denosumab is a human monoclonal antibody that neutralizes RANKL, a cytokine able to interact with the RANK receptor on preosteoclasts and osteoclasts, decreasing their recruitment and differentiation, leading to a decreased bone resorption. The aim of this observational real-life study was to analyze adherence to denosumab therapy and assess its efficacy in increasing bone mineral density (BMD) and modulating biochemical skeletal markers following previous treatments with bisphosphonates in a group of post-menopausal women with osteoporosis. Women were recruited in the specialized center from March 2012 to September 2019. Biochemical markers were recorded at baseline and every six months prior to subsequent drug injection. Dual X-ray absorptiometry was requested at baseline and after 18/24 months. Comparing BMD at baseline and after denosumab therapy in naive patients and in those previously treated with bisphosphonates, a positive therapeutic effect was observed in both groups. The results of our real-life study demonstrate, as expected, that BMD values significantly increased upon denosumab treatment. Interestingly, denosumab showed an increased efficacy in patients previously treated with bisphosphonates. Moreover, biochemical markers data indicate that osteoporotic patients, without other concomitant unstable health conditions, could be evaluated once a year, decreasing the number of specialistic center access. View Full-Text
Keywords: osteoporosis; anti-resorptive drugs; therapeutic adherence; bone mineral density; biochemical markers; serum parathyroid hormone; calcium; alkaline phosphatase; 25-hydroxy vitamin D osteoporosis; anti-resorptive drugs; therapeutic adherence; bone mineral density; biochemical markers; serum parathyroid hormone; calcium; alkaline phosphatase; 25-hydroxy vitamin D
Show Figures

Figure 1

MDPI and ACS Style

Marocco, C.; Zimatore, G.; Mocini, E.; Fornari, R.; Iolascon, G.; Gallotta, M.C.; Bimonte, V.M.; Baldari, C.; Lenzi, A.; Migliaccio, S. Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study. Int. J. Environ. Res. Public Health 2021, 18, 1728. https://doi.org/10.3390/ijerph18041728

AMA Style

Marocco C, Zimatore G, Mocini E, Fornari R, Iolascon G, Gallotta MC, Bimonte VM, Baldari C, Lenzi A, Migliaccio S. Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study. International Journal of Environmental Research and Public Health. 2021; 18(4):1728. https://doi.org/10.3390/ijerph18041728

Chicago/Turabian Style

Marocco, Chiara, Giovanna Zimatore, Edoardo Mocini, Rachele Fornari, Giovanni Iolascon, Maria C. Gallotta, Viviana M. Bimonte, Carlo Baldari, Andrea Lenzi, and Silvia Migliaccio. 2021. "Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study" International Journal of Environmental Research and Public Health 18, no. 4: 1728. https://doi.org/10.3390/ijerph18041728

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop